Summaries of the Section H (HML) update
Each month we issue a summary of the HML update. The table on this page gives a preview of the upcoming changes.
The table on this page gives a preview of the upcoming changes that will be announced in next month’s Section H of the Pharmaceutical Schedule.
The changes will be published in the Online HML(external link) around the 23rd of this month and are effective from next month.
For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz.
16 May 2025 - preview of changes for June 2025
|
Pharmaceutical |
Change |
|---|---|
|
Ambrisentan (Ambrisentan Viatris) tab 5 mg and 10 mg |
amended restriction criteria |
|
Aripiprazole (Abilify Maintena) inj 300 mg vial and 400 mg vial |
Pharmacodes delisted 1 June 2025
|
|
Atovaquone with proguanil hydrochloride tab 62.5 mg with proguanil hydrochloride 25 mg (Malarone Junior) and tab 250 mg with proguanil |
price increase |
|
Chlorhexidine with cetrimide irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule |
Brand change
|
|
Ciprofloxacin (Ciprofloxacin Kabi) inj 2 mg per ml, 100 ml bottle |
price increase |
|
Dabrafenib (Tafinlar) cap 50 mg and 75 mg |
new listing
|
|
Dexmedetomidine (Dexmedetomidine Viatris) inj 100 mcg per ml, 2 ml vial |
new Pharmacode listing (p’code 2696258) |
|
Enteral feed 1.2 kcal/ml (Jevity Plus RTH) liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bottle |
to be delisted 1 September 2025 |
|
Ethosuximide (Zarontin) cap 250 mg |
Pharmacode change
|
|
Famotidine (Famotidine Hovid MY) tab 40 mg |
new listing (p’code 2706229) |
|
Fludarabine phosphate (Fludarabine Sagent) inj 50 mg vial |
to be delisted 1 November 2025 |
|
Gentamicin sulphate (Gentamicin Hikma) inj 10 mg per ml, 2 ml ampoule |
delisted 1 June 2025 |
|
Haemophilus influenzae type B vaccine (Act-HIB) inj 10 mcg vial with diluent syringe |
new listing (p’code 2697955) |
|
Infliximab (Remicade) inj 100 mg vial |
amended restriction criteria |
|
Ipratropium bromide (Accord) nebuliser soln 250 mcg per ml, 2 ml ampoule |
new listing (p’code 2643154) |
|
Itraconazole (Itracap) cap 100 mg |
to be delisted 1 December 2025 |
|
Lithium carbonate (Douglas) cap 250 mg |
price increase |
|
Low electrolyte oral feed 1.8 kcal/ml (Nepro HP (strawberry) and Nepro HP (vanilla)) liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, 220 ml bottle |
amended prescription description |
|
Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and 10 ml vial |
amended restriction criteria |
|
Pembrolizumab (Keytruda) inj 25 mg per ml, 4 ml vial |
amended restriction criteria |
|
Phenytoin sodium (Hospira) inj 50 mg per ml, 2 ml ampoule |
to be delisted 1 February 2026 |
|
Phytomenadione (Konakion MM Paediatric) inj 2 mg in 0.2 ml ampoule |
amended brand name |
|
Propranolol (e.g. Hikma-Propranolol) oral liq 4 mg per ml |
listing of an example brand |
|
Sotalol (Sotalol Viatris) tab 80 mg |
new listing (p’code 2703580) |
|
Tocilizumab (Actemra) inj 20 mg per ml, 4 ml vial, 10 ml vial and 20 ml vial |
amended restriction criteria |
|
Trametinib (Mekinist) tab 0.5 mg and 2 mg |
new listing
|
|
Zoledronic acid (Zoledronic acid Viatris) inj 4 mg per 5 ml, vial |
new Pharmacode listing (p’code 2706032) |